Mobile

A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 and/or 0.5 mg) in patients with subfoveal choroidal neovascularization secon...

Update Il y a 4 ans
Reference: EUCTR2005-005921-73

A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 and/or 0.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to estimate the incidence of ocular adverse events (AEs) in patients with CNV secondary to AMD who are treated with 0.3 and/or 0.5 mg intravitreal ranibizumab.

Inclusion criteria

  • Male and female patients ≥50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

Links